Immunotherapy combo shows promise against tough rectal cancers

NCT ID NCT06770270

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether adding the immunotherapy drug pucotenlimab to standard chemoradiation can improve outcomes for people with locally advanced rectal cancer. About 68 participants will receive the combination, and doctors will check if the tumor disappears completely. If it works, some patients might avoid surgery altogether.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pucotenlimab (an immunotherapy drug) combined with chemotherapy and radiation
What this could lead to: If successful, this combination could help more patients with locally advanced rectal cancer achieve a complete response, potentially avoiding surgery and reducing the risk of recurrence.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 68 participants, so results may not apply to all patients. Immunotherapy can cause immune-related side effects, and the added benefit over standard treatment is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECTAL CANCER

Contacts and locations

Locations

Second Affiliated Hospital Of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.